The Rules Of The Biosimilar Suffix
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA guidance outlines dos and don’ts for proposing a nonproprietary name suffix for a biosimilar.
You may also be interested in...
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Final guidance adds new factors for biosimilar and innovative sponsors to consider in developing distinguishable suffixes for nonproprietary names but FDA is unswayed by calls for meaningful suffixes derived from license holder’s name; timing of retrospective application to previously approved products remains in question.
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Final guidance adds new factors for biosimilar and innovative sponsors to consider in developing distinguishable suffixes for nonproprietary names but FDA is unswayed by calls for meaningful suffixes derived from license holder’s name; timing of retrospective application to previously approved products remains in question.
Novavax Readying Multiple COVID-19 Vaccine Candidates To Ensure Fall Availability
CBER’s Marks said US FDA is working with Novavax on manufacturing to allow its protein-based vaccine to be ready for a fall roll-out. After some concerns about international coordination, multiple regulators seem to be settling on a monovalent approach for fall vaccinations.